Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Decitabine plus Crizotinib in EGFR-mutation-positive Advanced NSCLC
ChiCTR-OPC-16008567Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine and crizotinib in non-small cell lung cancer (NSCLC), sponsored by The Second Xiangya Hospital. Primary endpoint: median progression-free survival. Started Feb 2016; status: recruiting.
02
Drugs
decitabinecrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-16008567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-16008567.